Cancer Biology

Discussions of New Developments and Updates

Skip to content

Home
About
Topics
SHU Department of Biology

Tag Archives: MEDI4736

PD-L1 Inhibitor, avelumab, approved for Merkel cell carcinoma

Avelumab (Bavencio) is a PD-L1 inhibitor that was approved for the treatment of patients with metastatic Merkel cell carcinoma (MCC). Continue reading →

This entry was posted in active immunotherapy, Checkpoint Inhibitors, Immunology & Immunotherapy, Mutations, Tumor Suppressor Genes, Uncategorized and tagged atrezolizumab, avelumab, Bavencio, bladder cancer, checkpoint inhibitor, classical Hodgkin lymphoma, darvalumab, gastric cancer, HCC, hepatocellular carcinoma, HNSCC, Keytruda, MCPyV, MCV, MEDI4736, melanoma, Merkel cell carcinoma, Merkel cell polyomavirus, nivolumab, non-small cell lung cancer, NSCLC, Opdivo, PD-L1, Pembrolizumab, Renal cell carcinoma, squamous cell carcinoma of the head and neck, Tecentriq on April 5, 2017 by Joseph Gulfo.

Search for:

This blog is designed to provide updates in developments in cancer biology and engage in discussions about new findings in the field.

Sponsored by the Department of Biology, Seton Hall University.

@josephgulfo

[fts_twitter twitter_name=@josephgulfo tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]

Proudly powered by WordPress

Pin It on Pinterest